Elizabeth Thurgar tells us about her ISPOR poster reviewing fast-track appraisals at NICE and the evolution of cost comparison
Read More
The proposed new NHS England (NHSE) systems for specialised commissioning are arguably the highest risk of all current dynamics, both for the NHS and for suppliers. Key aspects of policy...
Read More
The Mtech Access team reflect on a energising and inspiring ISPOR Europe – with commentary from top 10 influencer Prof Phil Richardson
With so many patients left waiting for NHS care, what will the long-term impact be? How can Pharma and Medtech support the NHS with systematic challenges, like waiting? Where can...
Read More
On 29th September 2022, we brought together market access professionals from across Pharma and Medtech for our NHS Engagement Symposium: ‘People, pathways and payments – Mastering the key pillars of…
In the field of systematic reviews and evidence synthesis, strong, multi-partner teams are critical for moving new drugs from early development and testing in the lab to treating people in…
Inspired by the oral presentations and panel discussions at the recent HTAi Conference in Utrecht, The Netherlands, Persefoni Ioannou (Consultant – Health Technology Assessment [HTA]) shares some key trends in...
Read More
Tom Clarke (Director, NHS Insight & Interaction) explores what new integrated care legislation means for UK market access and for industry engagement with NHS decision-makers across England. July 1st saw...
Read More
How will the legislation of Integrated Care Systems in July 2022, and the ‘New NHS’ impact on Pharma market access? NHS England is going through its most significant changes for...
Read More
People, pathways, and payments – Mastering the key pillars of NHS engagement in 2023 Pharma and Medtech market access professionals joined us and our guest speakers from across the NHS...
Read More
